Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

A. Bizieux



Author of

  • +

    P1.01 - Poster Session with Presenters Present (ID 453)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Epidemiology/Tobacco Control and Cessation/Prevention
    • Presentations: 1
    • +

      P1.01-038 - Prognosis Value of Body Mass Index (BMI) and Weight Loss at Diagnosis in Primary Lung Cancer: Results of KBP-2010-CPHG Study (ID 4373)

      14:30 - 14:30  |  Author(s): A. Bizieux

      • Abstract
      • Slides

      Background:
      We studied the relationship between 1-year mortality and weight at diagnostic in 6,965 adult patients followed for primary lung cancer in 104 general hospitals.

      Methods:
      Patients were classified into 5 groups: Group 1, underweight with recent weight loss; Group 2, underweight without recent weight loss; Group 3, normal weight; Group 4, overweight; Group 5, obese. Kaplan-Meier method (1-year mortality) and Cox multivariate analysis (independent risk-factors) were used.

      Results:
      Respectively, 11%, 4%, 45%, 29%, and 12% of patients belonged to Groups 1, 2, 3, 4, and 5. One-year survival was lower in Group 1 (27% [24%-30%]) and higher in Group 4 (50% [48%-52%]) or 5 (53% [50%-57%]) than in Group 2 (47% [41%-53%]) or 3 (43% [42%-45%]) (Fig. 1). As compared with normal weight, overweight was an independent protective factor. Independent protective/risk factors are presented in Table 1. Interaction analyses showed that overweight was a significant independent protective factor for stage IIIA and IIIB cancer (HR=0.77 [0.6-0.99], p=0.038; HR=0.75 [0.59-0.97], p=0.029, respectively). Figure 1

      Variable HR 95%CI P
      BMI (group)
      3 1
      1 1.06 0.96-1.17 0.26
      2 1.03 0.85-1.23 0.789
      4 0.92 0.85-0.99 0.036
      5 0.9 0.81-1.01 0.061
      Age (years)
      <=40 1
      41-50 1.07 0.74-1.54 0.714
      51-60 1.02 0.72-1.46 0.899
      61-70 1.05 0.74-1.49 0.796
      71-80 1.11 0.78-1.59 0.553
      >80 1.54 1.07-2.22 0.02
      Sex
      Men 1
      Women 0.81 0.74-0.88 <0.001
      Smoking
      Never-smoker 1
      Former-smoker 1.19 1.06-1.35 0.004
      Current-smoker 1.27 1.13-1.44 <0.001
      PS
      PS0 1
      PS1 1.58 1.45-1.73 <0.001
      PS2 2.66 2.4-2.95 <0.001
      PS3 5.6 4.95-6.34 <0.001
      PS4 10.61 8.62-13.05 <0.001
      Stage
      <=IIB 1
      IIIA 1.89 1.61-2.21 <0.001
      IIIB 3 2.56-3.52 <0.001
      IV 4.71 4.13-5.38 <0.001




      Conclusion:
      In 2010, in France, in real life conditions, 1-year survival was low in lung cancer patients with low BMI at diagnosis and recent weight loss. Overweight appeared to be a protective factor in particular for stage IIIA and IIIB cancers.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.02a - Poster Session with Presenters Present (ID 470)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P3.02a-004 - NSCLC Patients Harboring ALK Translocation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14 (ID 5043)

      14:30 - 14:30  |  Author(s): A. Bizieux

      • Abstract

      Background:
      ALK (Anaplastic Lymphoma Kinase) translocation is a rare oncogenic driver in NSCLC (Non Small Cell Lung Cancer) (3 to 5%) and few data are published on the management of these patients outside patients included in clinical trial. objective:to investigate clinical characteristics and management of these patients in real world setting.

      Methods:
      inclusion of patients with a diagnosis of NSCLC harboring ALK translocations between January 2012 and December 2014, collection of demographic and clinical characteristics, risk factors, Progression free survival (PFS), Overall Survival (OS), mode of progression and therapeutic management

      Results:
      132 patients recruited in 31 centers: 67(51%) men; age: 60.1 ± 14,5 years; PS 0/1 at diagnosis: 89%; non smokers:79%, adenocarcinoma: 93%; Stage at diagnosis 4/3/2-1:74%/19%/7%: co-mutations EGFR n=2, BRAF n=2, KRAS = 1, HER2 = 1. Outcomes of stage IV (n=97): first line treatment: chemotherapy: 75%, Best supportive care (BSC): 1 %, anti ALK: 24 %; response rate, disease control rate (DCR) and PFS to first line treatment: 42 %,64% and 7.5 months (CI 5.9 ;9.5), second line treatment (n=60): chemotherapy: 25%, anti BRAF 72%, BSC 3 %; response rate, DCR and PFS to second line treatment: 43.4%,70% and 4,7 months (CI 4.0; 8.1); 2 years-OS: 56.7% (CI 45.5 ;70.4), mediane OS was not reach.

      Conclusion:
      In this real world analysis, the majority of NSCLC patients with ALK translocation were non smokers,adenocarcinoma and appears to have a better survival to NSCLC pts without oncogenic driver. Clinical trial information: Supported by an academic grant from Lilly, Astra Zeneca, boehringer ingelheim